Comparative Pharmacology
Head-to-head clinical analysis: SAFINAMIDE versus SAFINAMIDE MESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SAFINAMIDE versus SAFINAMIDE MESYLATE.
SAFINAMIDE vs SAFINAMIDE MESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Safinamide is a selective, reversible monoamine oxidase B (MAO-B) inhibitor and a glutamate release inhibitor. It inhibits MAO-B, leading to increased dopamine levels in the striatum, and also modulates glutamate release via use-dependent blockade of voltage-gated sodium channels.
Selective and reversible monoamine oxidase B (MAO-B) inhibitor. Increases dopamine levels in the striatum by inhibiting its metabolism. Also blocks voltage-dependent sodium and calcium channels, modulating neurotransmitter release.
50 mg orally once daily initially; after 2 weeks, may increase to 100 mg once daily. Maximum dose: 100 mg daily.
50 mg orally once daily; may increase to 100 mg orally once daily after 2 weeks based on tolerability and efficacy.
None Documented
None Documented
Clinical Note
moderateSafinamide + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Safinamide."
Clinical Note
moderateSafinamide + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Safinamide."
Clinical Note
moderateSafinamide + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Safinamide."
Clinical Note
moderateSafinamide + Cyclosporine
Terminal elimination half-life is 22-27 hours, allowing once-daily dosing. Steady-state reached within 5-7 days.
Terminal elimination half-life is approximately 20–26 hours (mean ~22 hours), allowing once-daily dosing. Steady-state is achieved within 3–5 days.
Primarily renal: 76-87% of the dose is excreted in urine as metabolites (mainly safinamide acid and O-demethylated safinamide glucuronide); <5% as unchanged drug. Fecal excretion accounts for 14-23%.
Primarily hepatic metabolism (approx. 90% via amide hydrolysis and oxidation, mainly CYP3A4), followed by renal excretion of metabolites. Less than 7% of the dose is excreted unchanged in urine. Biliary/fecal excretion accounts for roughly 50% of the administered dose, with the remainder eliminated via renal excretion of metabolites.
Category C
Category C
MAO-B Inhibitor Antiparkinsonian
MAO-B Inhibitor Antiparkinsonian
"The metabolism of Cyclosporine can be decreased when combined with Safinamide."